Esoforty-D 10 Capsules

babies: not applicable. lactating mothers: this medication is safe to use in breastfeeding mothers.
seek a doctor's advice before using this medicine. pregnancy: it is unsafe to use this medication in pregnancy.
limited studies showed that drugs affect developing fetuses. consult your physician before using this medicine.
driving: it is unsafe to drive while using this medication, as it alters alertness, makes you feel dizzy and sleepy. alcohol: advise caution.
consult your doctor before taking alcohol with this medication. liver: use this medication with caution in liver disease patients. you may require dose adjustments in some cases.
consult your doctor before using this medication. kidney: use this medication with caution in kidney disease patients.
you may require dose adjustments in some cases. consult your doctor before using this medication.
.

Headache Dizziness Diarrhoea Dry mouth Stomach pain Flatulence Sleepiness.

ESOFORTY D capsule is a prokinetic & proton pump inhibitor medication. It helps in the easy passage of food through the stomach by improving the motility of the stomach and intestines.
It also relieves indigestion and heartburn caused due to acidity by reducing the acid production in the stomach..

If you miss a dose, take it as soon as possible. If it is near the time of the next dose, then skip the missed dose.
Take the prescribed dose on your regular time daily. Don't double the dose to catch up with the missed dose..

• ESOFORTY D capsule is prokinetic & proton pump inhibitors. it is helpful to treat gastroesophageal reflux disease (gerd).
• take this medication before food. • take this medication as prescribed by your doctor.
• avoid discontinuation of this medication without consulting your doctor. • inform your doctor if the condition does not improve even after 14 days of medication usage.
• avoid alcohol while taking this medication. • do not do tasks that require mental focus if you develop dizziness after taking this medication..

contraindicated • (domperidone + esomeprazole sodium) + rilpivirine: concurrent use of these drugs may result in reduced rilpivirine plasma concentration major • (domperidone + esomeprazole sodium) + citalopram: concurrent use of these drugs may result in increased citalopram exposure and increase the risk of qt interval prolongation • (domperidone + esomeprazole sodium) + ketoconazole: concurrent use of these drugs may result in reduced ketoconazole plasma concentration • (domperidone + esomeprazole sodium) + methotrexate: concurrent use of these drugs may result in increased methotrexate exposure and increase the risk of methotrexate toxicity moderate • (domperidone + esomeprazole sodium) + ampicillin: concurrent use of these drugs may result in reduced ampicillin efficacy • (domperidone + esomeprazole sodium) + iron: concurrent use of these drugs may result in reduced iron bioavailability • (domperidone + esomeprazole sodium) + levothyroxine: concurrent use of these drugs may result in reduced levothyroxine effectiveness • (domperidone + esomeprazole sodium) + voriconazole: concurrent use of these drugs may result in increased voriconazole plasma concentration • (domperidone + esomeprazole sodium) + warfarin: concurrent use of these drugs may result in increased prothrombin time and inr minor • (domperidone + esomeprazole sodium) + ponatinib: concurrent use of these drugs may result in reduced ponatinib efficacy.